Dr. Evans is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Pringle Way
Ste 706
Reno, NV 89502Phone+1 775-982-5770Fax+1 775-982-5775
Summary
- I am a board certified urologist, with a fellowship specializing in oncology. I focus on treating prostate, bladder, kidney and testicular cancers. I am Professor and Chairman of the UC Davis School of Medicine Department of Urologic Surgery and President of the Society of Urologic Oncology. I have an active molecular biology laboratory focused on prostate cancer.
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Complex General Surgical Oncology, 1995 - 1997
University of California (San Francisco)Residency, Urology, 1991 - 1995- University of California (San Francisco)Residency, Surgery, 1990 - 1991
Madigan Army Medical CenterInternship, Transitional Year, 1986 - 1987
Geisel School of Medicine at DartmouthClass of 1986
Certifications & Licensure
CA State Medical License 1990 - 2026
NV State Medical License 2024 - 2025
TX State Medical License 1996 - 1998- American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012
- Super Doctor SuperDoctors.com
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer Start of enrollment: 2016 Jun 22
Publications & Presentations
PubMed
- Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer.Pengfei Xu, Joy C Yang, Bo Chen, Shu Ning, Xiong Zhang
Nature Communications. 2024-08-05 - 7 citationsSecondary Bladder Cancer After Prostate Cancer Treatment: An Age-matched Comparison Between Radiation and Surgery.Steven Monda, Manolis Pratsinis, Hansen Lui, Onika Noel, Thenappan Chandrasekar
European Urology Focus. 2024-05-01 - 3 citationsIGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer.Amy R Leslie, Shu Ning, Cameron M Armstrong, Leandro S D'Abronzo, Masuda Sharifi
Iscience. 2024-02-16
Journal Articles
- KDM8/JMJD5 as a Dual Coactivator of AR and PKM2 Integrates AR/EZH2 Network and Tumor Metabolism in CRPCChristopher Evans, MD, Nature
Press Mentions
Early Career Investigator Receives Federal Funding to Research Lethal Prostate CancerJune 11th, 2021- Drug ISRIB Is a Memory Enhancer, Anti Cancer Agent, Protects Hearing and Perhaps Has Anti Aging EffectsDecember 27th, 2020
Research Finds ‘Achilles Heel’ for Aggressive Prostate CancerMay 14th, 2018
Grant Support
- Neurotrophins And Tyrosine Kinases In Prostate CancerNational Institute Of Diabetes And Digestive And Kidney Diseases2002–2006
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
